Global Immunocell Therapy 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI03245227

Publication Date:

March 22, 2024

Pages:

104

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Immunocell Therapy market size was valued at US$ 1835.2 million in 2023. With growing demand in downstream market, the Immunocell Therapy is forecast to a readjusted size of US$ 4449.1 million by 2030 with a CAGR of 13.5% during review period.
The research report highlights the growth potential of the global Immunocell Therapy market. Immunocell Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Immunocell Therapy. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Immunocell Therapy market.
Immune therapy is a new class of cancer treatment designed to boost or enhance the body鈥檚 immune system to more efficiently target and destroy cancerous cells. Many experts believe that immunotherapy represents the most promising new cancer treatment since the development of chemotherapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Immunocell Therapy market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Immunocell Therapy market. It may include historical data, market segmentation by Type (e.g., Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Immunocell Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Immunocell Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Immunocell Therapy industry. This include advancements in Immunocell Therapy technology, Immunocell Therapy new entrants, Immunocell Therapy new investment, and other innovations that are shaping the future of Immunocell Therapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Immunocell Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for Immunocell Therapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Immunocell Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Immunocell Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Immunocell Therapy market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Immunocell Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Immunocell Therapy market.
麻豆原创 Segmentation:
Immunocell Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
Others
Segmentation by application
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Immunocell Therapy 麻豆原创 Size 2019-2030
2.1.2 Immunocell Therapy 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Immunocell Therapy Segment by Type
2.2.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
2.2.2 Natural Killer (NK) Cell Therapy
2.2.3 Others
2.3 Immunocell Therapy 麻豆原创 Size by Type
2.3.1 Immunocell Therapy 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Immunocell Therapy 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Immunocell Therapy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Immunocell Therapy 麻豆原创 Size by Application
2.5.1 Immunocell Therapy 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Immunocell Therapy 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Immunocell Therapy 麻豆原创 Size by Player
3.1 Immunocell Therapy 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Immunocell Therapy Revenue by Players (2019-2024)
3.1.2 Global Immunocell Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Immunocell Therapy Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Immunocell Therapy by Regions
4.1 Immunocell Therapy 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Immunocell Therapy 麻豆原创 Size Growth (2019-2024)
4.3 APAC Immunocell Therapy 麻豆原创 Size Growth (2019-2024)
4.4 Europe Immunocell Therapy 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Immunocell Therapy 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Immunocell Therapy 麻豆原创 Size by Country (2019-2024)
5.2 Americas Immunocell Therapy 麻豆原创 Size by Type (2019-2024)
5.3 Americas Immunocell Therapy 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunocell Therapy 麻豆原创 Size by Region (2019-2024)
6.2 APAC Immunocell Therapy 麻豆原创 Size by Type (2019-2024)
6.3 APAC Immunocell Therapy 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Immunocell Therapy by Country (2019-2024)
7.2 Europe Immunocell Therapy 麻豆原创 Size by Type (2019-2024)
7.3 Europe Immunocell Therapy 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immunocell Therapy by Region (2019-2024)
8.2 Middle East & Africa Immunocell Therapy 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Immunocell Therapy 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Immunocell Therapy 麻豆原创 Forecast
10.1 Global Immunocell Therapy Forecast by Regions (2025-2030)
10.1.1 Global Immunocell Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Immunocell Therapy Forecast
10.1.3 APAC Immunocell Therapy Forecast
10.1.4 Europe Immunocell Therapy Forecast
10.1.5 Middle East & Africa Immunocell Therapy Forecast
10.2 Americas Immunocell Therapy Forecast by Country (2025-2030)
10.2.1 United States Immunocell Therapy 麻豆原创 Forecast
10.2.2 Canada Immunocell Therapy 麻豆原创 Forecast
10.2.3 Mexico Immunocell Therapy 麻豆原创 Forecast
10.2.4 Brazil Immunocell Therapy 麻豆原创 Forecast
10.3 APAC Immunocell Therapy Forecast by Region (2025-2030)
10.3.1 China Immunocell Therapy 麻豆原创 Forecast
10.3.2 Japan Immunocell Therapy 麻豆原创 Forecast
10.3.3 Korea Immunocell Therapy 麻豆原创 Forecast
10.3.4 Southeast Asia Immunocell Therapy 麻豆原创 Forecast
10.3.5 India Immunocell Therapy 麻豆原创 Forecast
10.3.6 Australia Immunocell Therapy 麻豆原创 Forecast
10.4 Europe Immunocell Therapy Forecast by Country (2025-2030)
10.4.1 Germany Immunocell Therapy 麻豆原创 Forecast
10.4.2 France Immunocell Therapy 麻豆原创 Forecast
10.4.3 UK Immunocell Therapy 麻豆原创 Forecast
10.4.4 Italy Immunocell Therapy 麻豆原创 Forecast
10.4.5 Russia Immunocell Therapy 麻豆原创 Forecast
10.5 Middle East & Africa Immunocell Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Immunocell Therapy 麻豆原创 Forecast
10.5.2 South Africa Immunocell Therapy 麻豆原创 Forecast
10.5.3 Israel Immunocell Therapy 麻豆原创 Forecast
10.5.4 Turkey Immunocell Therapy 麻豆原创 Forecast
10.5.5 GCC Countries Immunocell Therapy 麻豆原创 Forecast
10.6 Global Immunocell Therapy Forecast by Type (2025-2030)
10.7 Global Immunocell Therapy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Immunocell Therapy Product Offered
11.1.3 Novartis Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Immunocell Therapy Product Offered
11.2.3 Gilead Sciences Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb Immunocell Therapy Product Offered
11.3.3 Bristol-Myers Squibb Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Bristol-Myers Squibb Main Business Overview
11.3.5 Bristol-Myers Squibb Latest Developments
11.4 J & J
11.4.1 J & J Company Information
11.4.2 J & J Immunocell Therapy Product Offered
11.4.3 J & J Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 J & J Main Business Overview
11.4.5 J & J Latest Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Information
11.5.2 JW Therapeutics Immunocell Therapy Product Offered
11.5.3 JW Therapeutics Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 JW Therapeutics Main Business Overview
11.5.5 JW Therapeutics Latest Developments
11.6 FOSUNKite
11.6.1 FOSUNKite Company Information
11.6.2 FOSUNKite Immunocell Therapy Product Offered
11.6.3 FOSUNKite Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 FOSUNKite Main Business Overview
11.6.5 FOSUNKite Latest Developments
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Information
11.7.2 CARsgen Therapeutics (Pipeline) Immunocell Therapy Product Offered
11.7.3 CARsgen Therapeutics (Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 CARsgen Therapeutics (Pipeline) Main Business Overview
11.7.5 CARsgen Therapeutics (Pipeline) Latest Developments
11.8 Autolus Therapeutics(Pipeline)
11.8.1 Autolus Therapeutics(Pipeline) Company Information
11.8.2 Autolus Therapeutics(Pipeline) Immunocell Therapy Product Offered
11.8.3 Autolus Therapeutics(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Autolus Therapeutics(Pipeline) Main Business Overview
11.8.5 Autolus Therapeutics(Pipeline) Latest Developments
11.9 Sorrento Therapeutics(Pipeline)
11.9.1 Sorrento Therapeutics(Pipeline) Company Information
11.9.2 Sorrento Therapeutics(Pipeline) Immunocell Therapy Product Offered
11.9.3 Sorrento Therapeutics(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Sorrento Therapeutics(Pipeline) Main Business Overview
11.9.5 Sorrento Therapeutics(Pipeline) Latest Developments
11.10 Mustang Bio(Pipeline)
11.10.1 Mustang Bio(Pipeline) Company Information
11.10.2 Mustang Bio(Pipeline) Immunocell Therapy Product Offered
11.10.3 Mustang Bio(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Mustang Bio(Pipeline) Main Business Overview
11.10.5 Mustang Bio(Pipeline) Latest Developments
11.11 Bluebird Bio(Pipeline)
11.11.1 Bluebird Bio(Pipeline) Company Information
11.11.2 Bluebird Bio(Pipeline) Immunocell Therapy Product Offered
11.11.3 Bluebird Bio(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Bluebird Bio(Pipeline) Main Business Overview
11.11.5 Bluebird Bio(Pipeline) Latest Developments
11.12 Cellectis(Pipeline)
11.12.1 Cellectis(Pipeline) Company Information
11.12.2 Cellectis(Pipeline) Immunocell Therapy Product Offered
11.12.3 Cellectis(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Cellectis(Pipeline) Main Business Overview
11.12.5 Cellectis(Pipeline) Latest Developments
11.13 Allogene Therapeutics(Pipeline)
11.13.1 Allogene Therapeutics(Pipeline) Company Information
11.13.2 Allogene Therapeutics(Pipeline) Immunocell Therapy Product Offered
11.13.3 Allogene Therapeutics(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Allogene Therapeutics(Pipeline) Main Business Overview
11.13.5 Allogene Therapeutics(Pipeline) Latest Developments
11.14 Celyad(Pipeline)
11.14.1 Celyad(Pipeline) Company Information
11.14.2 Celyad(Pipeline) Immunocell Therapy Product Offered
11.14.3 Celyad(Pipeline) Immunocell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Celyad(Pipeline) Main Business Overview
11.14.5 Celyad(Pipeline) Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.